Pfizers exit from neuroscience research calls into question the pharma industries commitment to hunt for new treatment.
Interesting article in the FT in Wednesday 17th jan 2018. It has been 15 years since a new drug was launched for Alzheimers, since then billions have been spent in the search for a drug to treat nearly 44mm sufferers. With a growing belief that patients are being identified and treated past the point of no return, some scientists are trying to identify individuals who seem healthy but who carry a genetic risk of getting Alzheimers, others are looking for the first signs of memory loss and starting treatment with new drugs to remove plaque build up in the memory before it becomes too late. One company ,Biogen, has drug called Aducanumab, which removes the plaque. It is currently in Phase III trials , the results should be known next year.
Prevention, stopping the plaque build up in the first place, seems the ideal solution. But in the meantime we should hope that Aducanumab trials give the desired results.
https://www.ft.com/content/c4e1241e-f731-11e7-88f7-5465a6ce1a00
Unlock Your Brainpower: Reserve Your Free Guide & Stay Updated on VITforD!
Subscribe and receive your FREE 27-page guide, “Enhancing Cognitive Health Through Nutritional Supplementation,” and be among the first to know when VITforD becomes available. We’ll also keep you informed about the latest research on brain health, vitamins, cognition, and dementia.